The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
16 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $20,181,096 in first-year total cost, median $1,351,071.
Most frequent study sections
- Special Emphasis Panel[ZAI1 AZ-M (S2)]9
- Special Emphasis Panel[ZAI1 AZ-M (S1)]6
- ZAI1-AZ-M(S1)1
Most frequent institutions
- ARIETIS1
- BAYLOR COLLEGE OF MEDICINE1
- GEORGIA STATE UNIVERSITY1
- HACKENSACK UNIVERSITY MEDICAL CENTER1
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Development of a safe and effective RBD-based vaccine against MERS-CoV1R56AI140872-01 | HOTEZ, PETER J | BAYLOR COLLEGE OF MEDICINE, TX | $549,181 | ZAI1 |
| 2019 | Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection1R01AI141236-01 | WEINER, DAVID B. | WISTAR INSTITUTE, PA | $1,541,486 | ZAI1 |
| 2019 | Development of ureadepsipetides for drug-resistant infections1R01AI141193-01 | LAFLEUR, MICHAELLEE, RICHARD E. | ARIETIS, MA | $1,529,042 | ZAI1 |
| 2019 | Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies1R01AI141251-01 | BRANCO, LUIS MANUEL | ZALGEN LABS, LLC, MD | $1,498,398 | ZAI1 |
| 2019 | New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae1R01AI141239-01 | DAIGLE, DENIS MARC | VENATORX PHARMACEUTICALS, INC., PA | $1,491,415 | ZAI1 |
| 2019 | Micro-Particle Delivery of a Potent Intracellular Adjuvant for a Universal Flu Vaccine1R01AI141333-01 | BACHELDER, ERICTING, JENNY P | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $1,473,686 | ZAI1 |
| 2019 | Advanced development of a viral entry inhibitor as a therapeutic for arenavirus hemorrhagic fever1R01AI141102-01 | AMBERG, SEAN M | KINETA, INC., WA | $1,370,459 | ZAI1 |
| 2019 | Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens1R01AI141183-01 | PERLIN, DAVID S | HACKENSACK UNIVERSITY MEDICAL CENTER, NJ | $1,362,765 | ZAI1 |
| 2019 | Universal room temperature stable influenza nanovaccine1R01AI141196-01 | NARASIMHAN, BALAJI | IOWA STATE UNIVERSITY, IA | $1,339,376 | ZAI1 |
| 2019 | Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa1R01AI141101-01 | GREENBERG, DAVID ELIHU | UT SOUTHWESTERN MEDICAL CENTER, TX | $1,204,439 | ZAI1 |
| 2019 | Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens1R01AI141202-01 | COOKE, TIMIBRAHIM, ASHRAF S. | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER, CA | $1,181,298 | ZAI1 |
| 2019 | Production of a Gonococcal Vaccine for Countering Antimicrobial Resistance1R01AI141229-01 | GRAY-OWEN, SCOTT DMORAES, TREVOR FSCHRYVERS, ANTHONY BERNARD | UNIVERSITY OF CALGARY, AB | $1,112,000 | ZAI1 |
| 2019 | Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza Viruses1R01AI141222-01 | PLEMPER, RICHARD K. | GEORGIA STATE UNIVERSITY, GA | $1,103,435 | ZAI1 |
| 2019 | Development of Inhaled CPZEN-45 For Tuberculosis Therapy1R01AI141082-01 | HICKEY, ANTHONY JAMES | RESEARCH TRIANGLE INSTITUTE, NC | $1,006,759 | ZAI1 |
| 2019 | A novel vaccine against multidrug-resistant gonorrhea1R01AI141181-01 | RAM, SANJAYRICE, PETER A. | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $967,287 | ZAI1 |
| 2017 | Toward a universal influenza virus vaccine based on live attenuated NS1-deleted influenza viruses1R01AI141226-01 | GARCIA-SASTRE, ADOLFO | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $1,450,070 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.